Oncolytics Biotech presents Phase 2 pelareorep colorectal cancer trial design at ESMO
ONCY•Oncolytics Biotech will present the design of its Phase 2 REO 033 trial at ESMO 2026, testing pelareorep plus standard chemotherapy and bevacizumab against standard treatment alone. The study targets 30 patients per arm, and recent FDA interactions opened a path to a pivotal expansion that could support accelerated approval.
1. Trial design
The randomized Phase 2 REO 033 study will test pelareorep with standard chemotherapy and bevacizumab against standard treatment alone in previously treated patients with RAS-mutant, microsatellite-stable metastatic colorectal cancer. The trial targets 30 patients per arm and aims to validate earlier findings suggesting improved tumor response and survival compared with historical treatment outcomes. Recent FDA interactions opened a path to a pivotal expansion that could support accelerated approval; full approval would depend on progression-free survival.
